Neuronetics (NASDAQ:STIM – Get Free Report)‘s stock had its “market perform” rating restated by William Blair in a note issued to investors on Tuesday, RTT News reports. Separately, Piper Sandler reiterated an “overweight” rating and issued a $8.00 target price (up previously from $7.00) on shares of Neuronetics in a research report on Wednesday, March […]
Neuronetics (NASDAQ:STIM – Get Free Report)‘s stock had its “market perform” rating restated by analysts at William Blair in a research note issued on Tuesday, RTT News reports. Separately, Piper Sandler reaffirmed an “overweight” rating and issued a $8.00 price target (up from $7.00) on shares of Neuronetics in a report on Wednesday, March 6th. […]
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and olderMALVERN, Pa., March 25, 2024 Neuronetics, Inc. , a medical technology company focused on.
Neuronetics, Inc. (STIM) announced clearance from the FDA for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder in adolescent patients aged 15-21.